Identifying The Prognostic Significance of Mitochondrial AAA Proteases YME1L1 Expression in Ovarian Cancer

Background: The discovery of early diagnosis and prognostic markers for ovarian cancer can significantly improve survival and reduce mortality. The role of the YME1L1 signaling axis in genetic alterations and immune infiltration of the tumor microenvironment remains unclear. Methods: : Bioinformatics web resources, including GEPIA2, cBioPortal, Oncomine, Kaplan–Meier Plotter and TIMER were used to analyze the expression profile, prognostic value and immune infiltration of YME1L1.We further performed tissue microarray analysis of paraffin-embedded tissues from 60 ovarian cancer patients recorded at FIGO/TNM cancer staging. Results: : Here, we use multi-omics analysis of multiple histological data to map the role of epigenetic and genetic alterations of YME1L1 in tumor immune infiltration and prognosis of cancer patients. We explored YME1L1 gene expression profiles by systematically analyzing the association of YME1L1 expression with the prognosis of ovarian cancer patients confirmed in multiple databases. High YME1L1 expression was associated with poorer overall survival and disease-free survival associated. Together, our studies suggest that YME1L1 may modulate tumor survival, immune features and contribute to tumor immune invasion, poor prognosis, and immunotherapy failure. Conclusion: Our findings may have clinical implications for the design of treatment strategies, prognosis assessment and follow-up management of patients receiving immunotherapy in a variety of cancers.